(MedPage Today) — In a phase III trial from China, triple therapy containing rifasutenizol — a novel antimicrobial designed for Helicobacter pylori — proved noninferior to bismuth plus clarithromycin-based triple therapy in the first-line…
Source link : https://www.medpagetoday.com/gastroenterology/generalgastroenterology/117423
Author :
Publish date : 2025-09-11 19:33:00
Copyright for syndicated content belongs to the linked Source.
